Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...

BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents, in the latest round of a ...

The 2nd U.S. Circuit Court of Appeals ruled in favor of Pfizer (PFE), in a lawsuit by Do No Harm challenging the company's diversity fellowship program. Read more here.

Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX), its partner for the Comirnaty COVID-19 vaccine, made legal submissions to London's Court of Appeal on Thursday seeking to overturn a prior court ruling ...

The lawsuit specifically seeks to allow Pfizer to reimburse members for heart failure drugs, which would otherwise cost $13,000 in Medicare copays a year, Fortune reported on July 28.

Pfizer and the direct purchasers entered into the settlement agreement Nov. 22. The agreement still needs official court approval. More articles on legal & regulatory issues: ...

In the latest chapter of the legal saga, Pfizer and BioNTech are pressing the U.S. Patent and Trademark Office (PTO) to invalidate a pair of Moderna patents tied to mRNA vaccine production.

In light of the rapid spread of the delta variant and full FDA approval of the Pfizer COVID-19 vaccine, many employers are either now implementing or considering a vaccine mandate.

Neither Pfizer nor its outside lawyers from Dechert and Paul, Weiss, Rifkind, Wharton & Garrison responded to my email query on the amicus filings. The company has until April 8 to respond to the ...

The group sued Pfizer over the company's Breakthrough Fellowship Program, which the company launched in 2021, arguing the program discriminated against white and Asian-American applicants in ...

Pfizer (PFE) and BioNTech (BNTX) challenge Moderna's patent win in London court over mRNA COVID-19 vaccine technology. Read more here.